Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 171 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Follow-Up Questions
Pliant Therapeutics Inc의 CEO는 누구입니까?
Dr. Bernard Coulie은 2016부터 회사에 합류한 Pliant Therapeutics Inc의 President입니다.
PLRX 주식의 가격 성능은 어떻습니까?
PLRX의 현재 가격은 $1.56이며, 전 거래일에 decreased 0.31% 하였습니다.
Pliant Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Pliant Therapeutics Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Pliant Therapeutics Inc의 시가총액은 얼마입니까?
Pliant Therapeutics Inc의 현재 시가총액은 $96.0M입니다
Pliant Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 Pliant Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 5명의 매수, 12명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
